Project Grant R15NS111413

Award Date 9/15/22
Completion Date 4/30/26
Dollars Obligated $876K
Federal Grant Program
93.853
Assistance Type
Project Grant
Place of Performance
Alabama, USA
Similar Awards
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, will support research to characterize the features of long-distance regressive signaling through the p75 neurotrophin receptor (p75NTR) and its role in nervous system development. The total award amount is $543,337 over the project period from January 1, 2025 to December 31, 2029. The...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $646,104 Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) to the San Diego Biomedical Research Institute, a non-profit research organization. The grant supports research to investigate how neuroinflammation mediated by the interleukin-13 receptor signaling pathway may contribute to the selective loss of dopaminergic neurons in Parkinson's disease. The...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $499,286.59 to the University of Pittsburgh to conduct research on the relationship between the LRRK2 protein and oxidative stress in Parkinson's disease pathogenesis. The project aims to elucidate how wild-type LRRK2 kinase activity is stimulated, where in the cell this occurs,...
This $792,498 Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) supports research by the Trustees of Indiana University, doing business as Indiana University Indianapolis, to investigate the role of P2X7 receptor signaling in neuroinflammation and neurodegeneration in Alzheimer's disease and related dementias (ADRD). The key objectives are to: 1) characterize mouse models of ADRD to assess neuroinflammation, synaptic density, and neuronal health...
This federal Project Grant award of $173,140 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program supports research to investigate the role of neural activity in the degeneration of midbrain dopamine neurons, which is a key feature of Parkinson's disease. The research project, which runs from September 30, 2024 to June 30, 2027, will utilize novel mouse models to...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program provides $144,362 to Drexel University to investigate the role of the PERK kinase in regulating the localization of neuroprotective growth factors in neurons. The 2-year and 7-month project, which began on July 17, 2024, aims to define how PERK interacts with the CaMKII kinase to...
This $432,418 Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) supports research at Vanderbilt University to discover and characterize small molecule modulators of the NURR1-RXR protein complex. The goal is to develop chemical tools that can be used to study the role of NURR1-RXR in regulating neuronal function and neuroinflammation, which are implicated in neurodegenerative diseases like Alzheimer's and Parkinson's. The 2-year project will...
This Project Grant award of $616,200.00 was provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program. The objective is to study the influence of neuromelanin, a dark pigment found in dopamine neurons, on the degeneration of these neurons in Parkinson's disease. The research will leverage a novel mouse model developed by a sub-awardee, Emory University,...
This Project Grant award, funded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, aims to investigate the role of synaptic organizers in Parkinson's disease pathology and potential therapeutic interventions. The total funding amount is $669,115, awarded on September 1, 2024 with a project period ending on August 31, 2029. The research project, led by Texas A&M...
This $475,475 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research at Beth Israel Deaconess Medical Center, Inc. (Bidmc) in Boston, Massachusetts. The goal of the award is to evaluate a small molecule inhibitor of the USP30 enzyme as a potential neuroprotective therapy for Parkinson's disease. The research will assess...

THE ROLE OF THE P75 NEUROTROPHIN RECEPTOR IN DOPAMINERGIC NEURODEGENERATION INDUCED BY OXIDATIVE STRESS. - NEURODEGENERATIVE DISEASES, WHICH ARE CHARACTERIZED BY PROGRESSIVE NEURAL DYSFUNCTION AND NEURONAL DEATH, ARE A COMMON CAUSE OF MORBIDITY AND MORTALITY IN THE ELDERLY. BECAUSE CURRENT TREATMENT STRATEGIES FOR MOST NEURODEGENERATIVE DISORDERS ARE PALLIATIVE RATHER THAN CURATIVE, THERE IS AN URGENT NEED FOR NOVEL TREATMENT STRATEGIES THAT REDUCE OR PREVENT PROGRESSIVE NEURODEGENERATION. THE P75 NEUROTROPHIN RECEPTOR (P75NTR) IS A TRANSMEMBRANE PROTEIN THAT HAS BEEN DEMONSTRATED TO REGULATE THE DEATH OF NEURONS AFFECTED BY A VARIETY OF PATHOLOGICAL CONDITIONS. DESPITE THIS KNOWN ROLE, HOW THE RECEPTOR IS ACTIVATED IN DAMAGED NEURONS AND THE MECHANISMS THROUGH WHICH IT REGULATES CELL DEATH ARE POORLY UNDERSTOOD. USING CULTURED DOPAMINERGIC CELLS, WE RECENTLY DISCOVERED A NOVEL, LIGAND-INDEPENDENT MECHANISM THROUGH WHICH P75NTR IS ACTIVATED IN RESPONSE TO OXIDATIVE STRESS. HOWEVER, THE SIGNALING EVENTS ASSOCIATED WITH THIS NEW RECEPTOR ACTIVATION MECHANISM AND THE PHYSIOLOGICAL CONSEQUENCES OF SUCH EVENTS REMAIN INCOMPLETELY UNDERSTOOD. INVESTIGATIONS IN THIS REGARD MAY BE PARTICULARLY IMPORTANT TO UNDERSTANDING THE PROGRESSION OF PARKINSON'S DISEASE, A DISORDER ASSOCIATED WITH OXIDATIVE STRESS AND PROGRESSIVE DEGENERATION OF DOPAMINERGIC NEURONS IN THE SUBSTANTIA NIGRA OF THE VENTRAL MIDBRAIN. WITH THESE CONSIDERATIONS, WE PROPOSE TO EVALUATE THE EFFECTS OF P75NTR ON DOPAMINERGIC NEURODEGENERATION IN CELL CULTURE AND ANIMAL MODELS OF PARKINSON'S DISEASE. AIM I OF THIS APPLICATION IS TO CHARACTERIZE THE MECHANISMS THROUGH WHICH OXIDATIVE STRESS INDUCES P75NTR SIGNALING. BIOCHEMICAL ASSAYS WILL BE PERFORMED USING LYSATES OF CULTURED CELLS TO IDENTIFY THE ROLES OF VARIOUS P75NTR INTERACTORS IN OXIDATIVE STRESS-INDUCED P75NTR SIGNALING. AIM II OF THE PROPOSED WORK IS TO USE BLOCKADE OF P75NTR SIGNALING BY SIRNA-MEDIATED KNOCKDOWN, GENETIC DELETION, OR PHARMACOLOGICAL INHIBITION TO EVALUATE THE EFFECTS OF THE RECEPTOR ON DOPAMINERGIC NEURODEGENERATION IN CELL CULTURE OR MOUSE MODELS OF PARKINSON'S DISEASE. SINCE AXONAL DEGENERATION IN DOPAMINERGIC NEURONS IS A KEY, EARLY-STAGE EVENT THAT PRECEDES NEURONAL DEATH IN INDIVIDUALS WITH PARKINSON'S DISEASE, AIM III OF THE PROPOSED RESEARCH PROJECT IS TO EVALUATE THE EFFECTS OF P75NTR SIGNALING ON AXONAL DEGENERATION INDUCED BY OXIDATIVE STRESS. ALL STUDIES IN THIS PROPOSAL WILL INVOLVE UNDERGRADUATE STUDENTS AT EASTERN KENTUCKY UNIVERSITY (EKU). THESE STUDENTS WILL ALSO PARTICIPATE IN WEEKLY LAB MEETINGS AND RECEIVE PERSONAL MENTORSHIP IN SCIENCE LITERACY, EXPERIMENTAL DESIGN, RESEARCH METHODOLOGY, DATA ANALYSIS, AND COMMUNICATION OF FINDINGS. BY SUPPORTING THIS MERITORIOUS RESEARCH, AN AREA GRANT WOULD PROVIDE IMPACTFUL RESEARCH EXPERIENCES FOR STUDENTS AND STRENGTHEN THE SCIENTIFIC ENVIRONMENT AT EKU, AN INSTITUTION WITH ACCELERATING EMPHASIS ON BIOMEDICAL RESEARCH.

Posted 9/14/22, 12:00 AM